prohibits frivolous suits that restrict access to biogenerics and
delay competition in the marketplace.
6. Creates a balanced process that encourages innovation by both brand
and generic companies and expands access to prescription medications
7. Does not create a system of endless monopoly pricing and no
opportunity for competition to enter the marketplace.
The following is the text of the latest CCPM ad:
What If Patients Had Wings?
Executives from the multi-billion dollar pharmaceutical and biotech
industry are descending on Congress...flying to Washington to make sure
their monopolies are protected.
Meanwhile countless Americans are struggling to pay for high-priced
These patients can't fly to Washington on their own, but they are making
their voices heard.
Numerous organizations representing patients, seniors, consumers, labor,
and businesses support legislation to establish a workable approval
pathway for biogenerics.
Americans need balanced legislation that fosters innovation without
excessive market exclusivity which does nothing more than extend
monopolies, stifle competition and keep patients waiting for affordable
BIO and PhRMA say that want a biogenerics pathway, but their policy is an
empty promise to patients.
CCPM supports public policies that facilitate timely access to affordable pharmaceuticals. Visit http://www.competitiverx.com for more information and a list of CCPM members.
Contact: Katie Braden Huffard, 202-255-5216;
Andrea Hofelich, 703-647-2495; Charles Cote, 202-207-3605
|SOURCE The Coalition for a Competitive Pharmaceutical Market(CCPM)|
Copyright©2008 PR Newswire.
All rights reserved